Thermo Fisher Scientific’s clinical research business named a leader among CROs in 2026 ISG Provider Lens report for use of AI in clinical trials

Thermo Fisher Scientific has earned a leader designation among contract research organisations (CROs) in the 2026 ISG Provider Lens Life Sciences Digital Services report, reflecting the company’s ongoing investment in digital innovation across the clinical development continuum.

The recognition centres on the strength of Thermo Fisher’s PPD clinical research business, which was acknowledged for its capabilities in clinical development, patient engagement, and digital advancement in pharmacovigilance and regulatory affairs. The independent study, carried out by Information Services Group (ISG), assesses leading providers on the basis of technology innovation, portfolio strength and competitive positioning.

ISG highlighted Thermo Fisher’s end-to-end approach to clinical development, including its capacity to integrate decentralised and hybrid trial models with advanced data and analytics. By embedding digital technologies and AI-driven insights throughout the clinical trial lifecycle, the company helps clients reduce operational complexity and improve the predictability of global development programmes.

In patient engagement, the report noted Thermo Fisher’s data-driven strategies for supporting recruitment and retention, alongside digital platforms designed to broaden access to clinical trials. These approaches aim to speed up enrolment timelines while ensuring study designs are optimised to include all clinically relevant populations.

The company was also recognised for its advances in pharmacovigilance and regulatory affairs, where it continues to develop the use of artificial intelligence and machine learning to support safety case processing, signal detection and regulatory intelligence. These capabilities enable more proactive risk management and help maintain compliance across global markets.

“This recognition affirms our leadership as a global CRO advancing digital clinical trials through AI and data-driven innovation across every stage of development,” said Krishna Cheriath, vice president and head of clinical research digital and AI at Thermo Fisher Scientific. “We are focused on building a more connected, patient-centric and AI-enabled future for clinical research that helps our customers accelerate the delivery of safe and effective therapies to patients worldwide.”

“The PPD clinical research business exemplifies the next-generation CRO model, where operational scale is enhanced by data, AI and patient-centric design to deliver predictable, high-quality clinical outcomes at global scale,” said ISG lead analyst Sneha Jayanth.

---

---

Related Topics and Keywords

AI in clinical trials, CROs, Thermo Fisher Scientific